Floatz logo
Floatz Rating
B57/100
Confidence
Indicative
v0.2
Sponsor
DuKang Pharmaceuticals, Inc.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06285916CT.gov
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.

Same indication · Postpartum Depression

AssetSponsorPhaseRating
Nora520 (this asset)DuKang Pharmaceuticals, Inc.P2B · 57
Allopregnan-3.Alpha.-Ol-20-OneSupernus Pharmaceuticals, Inc.P3BBB
SertralineLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP4BB
ZuranoloneBiogenP3BB
GabapentinStanford UniversityP4BB
EscitalopramLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP3BB
Lpcn 1154ALipocine Inc.P3BB
CelecoxibLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP3B
(±)-2-(O-Chlorophenyl)-2-(Methylamino)CyclohexanoneGrace Lim, MD, MSP2B

+4 more in the Postpartum Depression cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Nora520 in Postpartum Depression. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nora520-postpartum-depression

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →